KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Gsk (GSK) EBT Margin (2016 - 2026)

Gsk has reported EBT Margin over the past 18 years, most recently at 28.1% for Q1 2026.

  • For Q1 2026, EBT Margin rose 6.0% year-over-year to 28.1%; the TTM value through Mar 2026 reached 22.73%, up 596.0%, while the annual FY2025 figure was 22.66%, 1157.0% up from the prior year.
  • EBT Margin for Q1 2026 was 28.1% at Gsk, up from 11.02% in the prior quarter.
  • Over five years, EBT Margin peaked at 29.12% in Q1 2022 and troughed at 0.8% in Q3 2024.
  • A 5-year average of 21.01% and a median of 21.98% in 2023 define the central range for EBT Margin.
  • Biggest five-year swings in EBT Margin: tumbled -2118bps in 2024 and later soared 2794bps in 2025.
  • Year by year, EBT Margin stood at 21.18% in 2022, then skyrocketed by 30bps to 27.56% in 2023, then tumbled by -32bps to 18.69% in 2024, then tumbled by -41bps to 11.02% in 2025, then surged by 155bps to 28.1% in 2026.
  • Business Quant data shows EBT Margin for GSK at 28.1% in Q1 2026, 11.02% in Q4 2025, and 28.74% in Q3 2025.